Hepatic inflammatory responses in liver fibrosis

L Hammerich, F Tacke - Nature Reviews Gastroenterology & …, 2023 - nature.com
Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

[HTML][HTML] Changing epidemiology, global trends and implications for outcomes of NAFLD

VWS Wong, M Ekstedt, GLH Wong, H Hagström - Journal of hepatology, 2023 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver
disease globally and is currently estimated to affect 38% of the global population. Only a …

Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH

R Loomba, AJ Sanyal, KV Kowdley… - … England Journal of …, 2023 - Mass Medical Soc
Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

[HTML][HTML] The global burden of liver disease

ZM Younossi, G Wong, QM Anstee, L Henry - Clinical Gastroenterology and …, 2023 - Elsevier
Chronic liver disease (CLD) and its associated complications (cirrhosis and liver cancer)
cause significant mortality, morbidity, and economic burden. Published data from the World …

Lifestyle interventions in nonalcoholic fatty liver disease

ZM Younossi, S Zelber-Sagi, L Henry… - Nature Reviews …, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) is a dynamic chronic liver disease that develops in
close association with metabolic irregularities. Between 2016 and 2019, the global …

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

G Feng, L Valenti, VWS Wong, YM Fouad… - Nature Reviews …, 2024 - nature.com
Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

F Tacke, T Puengel, R Loomba, SL Friedman - Journal of Hepatology, 2023 - Elsevier
Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …

Hepatocellular carcinoma surveillance—Utilization, barriers and the impact of changing aetiology

DQ Huang, AG Singal, F Kanwal… - Nature Reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

LA Díaz, JP Arab, A Louvet, R Bataller… - Nature Reviews …, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the
leading causes of chronic liver disease worldwide. NAFLD and ALD share …

[HTML][HTML] Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten?

C Koliaki, M Dalamaga, S Liatis - Current Obesity Reports, 2023 - Springer
Abstract Purpose of Review To provide an update on current obesity prevalence trends and
summarize the available evidence suggesting a possible plateau or stabilization in obesity …